Tokai Pharmaceuticals is focused on developing novel, proprietary therapies for prostate cancer and other hormonally-driven diseases. The company's lead drug candidate, galeterone, is currently being evaluated in an ongoing Phase 2 study, called ARMOR2, in patients with castration resistant prostate cancer (CRPC). The company plans to initiate a pivotal clinical trial of galeterone in the first half of 2015.